$2.5M seed financing round closed by Cleara Biotech-targets cellular senescence
Longevity Technology - 03-Oct-2022Cleara’s novel FOXO4-based treatment approach-ability to eliminate biomarker-positive scarred cells
Cleara Biotech
Cleara is developing therapeutics to eliminate senescent cells.
Cleara Biotech discovered a mechanism that shows how senescent cells escape the natural elimination process. Based on this discovery, Cleara is developing therapeutics to treat patients with a range of diseases caused by this failure to clear senescent cells.
Visit website: https://www.clearabiotech.com/
Details last updated 03-May-2019
People at Cleara Biotech
Cleara Biotech News
LMC provides background and success outlook on 14 leading senolytic companies
Longevity Marketcap - 15-Dec-2020Comprehensive review of companies' clinical and financial state of play
Nature Biotechnology reviews the state of play of senolytics
Nature Biotechnology - 12-Nov-2020In August, Unity announced that its lead drug candidate had failed to beat a placebo in reducing ...
Labiotech gathers feedback from European biotechs on Unity failure
Labiotech - 28-Aug-2020General feeling that failures are bound to happen - but that their approaches can succeed
LEAF report from the Longevity Leaders Conference
Lifespan.io (LEAF) - 06-Feb-2019Encouraging signs from big companies - more interviews to follow
Cleara Biotech Joins the Race to Develop Senolytic Therapies
Lifespan.io (LEAF) - 09-Jul-2018This therapy uses a modified FOXO4 to promote apoptosis in senescent cells
Topics mentioned on this page:
Senescent Cells
